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We have investigated the gene for dystrobrevin-binding protein 1 (DTNBP1), or dysbindin, which has been strongly
suggested as a positional candidate gene for schizophrenia, in three samples of subjects with schizophrenia and
unaffected control subjects of German (418 cases, 285 controls), Polish (294 cases, 113 controls), and Swedish
(142 cases, 272 controls) descent. We analyzed five single-nucleotide polymorphisms (P1635, P1325, P1320, P1757,
and P1578) and identified significant evidence of association in the Swedish sample but not in those from Germany
or Poland. The results in the Swedish sample became even more significant after a separate analysis of those cases
with a positive family history of schizophrenia, in whom the five-marker haplotype A-C-A-T-T showed a P value
of .00009 (3.1% in controls, 17.8% in cases; OR 6.75; after Bonferroni correction). Our results suggestPp .00153
that genetic variation in the dysbindin gene is particularly involved in the development of schizophrenia in cases
with a familial loading of the disease. This would also explain the difficulty of replicating this association in
consecutively ascertained case-control samples, which usually comprise only a small proportion of subjects with a
family history of disease.
Chromosome 6p is one of the most consistently repli-
cated susceptibility regions in studies of schizophrenia
(locus SCZD3 [MIM 600511]). Initial linkage findings
by Straub et al. (1995), Wang et al. (1995), Schwab et
al. (1995), Moises et al. (1995), and The Schizophrenia
Linkage Collaborative Group for Chromosomes 3, 6,
and 8 (1996) were supported by a number of subsequent
individual linkage studies and by a recently performed
large meta-analysis of all completed schizophrenia ge-
nome scans (Lewis et al. 2003).
After their linkage finding in 270 Irish pedigrees with
a high frequency of schizophrenia, Straub et al. (2002)
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performed linkage disequilibrium (LD) studies in the
same sample and identified significant associations
between SNPs within the positional candidate gene
DTNBP1 (dystrobrevin-binding protein 1, also known
as “dysbindin” [MIM 607145]) on 6p22.3 and schizo-
phrenia. None of the associated variants appeared to
have a functional effect; all were located in noncoding
regions of the gene. The pattern of LD was complex and
consistent with the presence of more than one suscep-
tibility allele.
Since then, two replication studies have been pub-
lished: Schwab et al. (2003) tested six SNPs in two in-
dependent parent-offspring trio samples from Germany,
one derived from 78 linked affected-sib-pair families, the
second representing an independently ascertained sam-
ple of 125 trios with a family history of psychiatric dis-
orders. Evidence of association was obtained by single-
marker and haplotype analyses. Schwab et al. (2003)
found association with alleles different from those re-
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ported by Straub et al. (2002). An explanation could be
the presence of different susceptibility alleles in the Irish
and German populations.
A second study by Morris et al. (2003) tried to rep-
licate the finding by Straub et al. (2002) in a case-control
sample of schizophrenia from the Irish population. They
tested eight SNPs, five of which were identical to SNPs
genotyped by Straub et al. (2002), in 219 Irish schizo-
phrenia cases and 231 controls. No evidence was found
to suggest an association between the dysbindin gene
and schizophrenia in their sample. This was surprising
because intermarker LD of the tested SNPs appeared to
confirm that the samples of Straub et al. (2002) and
Morris et al. (2003) had been drawn from the same
homogeneous population. The major difference between
the study by Morris et al. (2003) and those by Straub
et al. (2002) and Schwab et al. (2003) was that the
sample of Morris et al. was not selected for familiality.
The question therefore was whether this result may re-
flect different genetic mechanisms underlying schizo-
phrenia in individuals derived from high-density families
and in individuals not selected for a family history of
disease; however, a separate analysis, using the family
history–positive cases only, also failed to provide evi-
dence of association (Morris et al. 2003), but definite
conclusions were difficult to draw because of the small
sample size.
In the present study, we have attempted to perform
an independent replication of the results obtained by
Straub et al. (2002) and Schwab et al. (2003) in three
samples of schizophrenic cases and controls from Ger-
many, Poland, and Sweden, including a total of 854 cases
and 670 controls.
The German sample comprised 418 cases and 285
controls, all of German descent. All patients were in-
terviewed by experienced psychiatrists using the Struc-
tured Clinical Interview for DSM-IV (Diagnostic and
Statistical Manual, 4th edition) Disorders (SCID I) (Amer-
ican Psychiatric Association 1994; First et al. 1997). Life-
time “best estimate” diagnoses, according to DSM-IV
criteria (American Psychiatric Association 1994), were
based on multiple sources of information, including the
SCID I, medical records, and family history. All pro-
bands had a schizophrenic ( ), schizophreni-Np 336
form ( ), or schizoaffective disorder ( ).Np 7 Np 75
Two hundred nineteen (52.4%) of the cases were female,
and 199 (47.6%) were male. The controls included 113
females (39.7%) and 172 males (60.3%).
The Polish sample comprised 294 probands and 113
controls of Polish descent. Phenotype characterization
was identical to the procedure in the German probands.
The Polish proband sample consisted of 291 individuals
with schizophrenic and 3 with schizoaffective disorder;
there were 120 (40.8%) females and 174 (59.2%) males.
The control sample comprised 71 (62.8%) females and
42 (37.2%) males.
The Swedish probands ( ; 54 [38.0%] fe-Np 142
males, 88 [62.0%] males) were all of Swedish descent.
Lifetime “best estimate” diagnoses were based on DSM-
III-R criteria (American Psychiatric Association, 1987).
All probands had a schizophrenic ( ), schizo-Np 130
phreniform ( ), or schizoaffective disorder (Np 5 Np
). There were 272 controls available, 123 (45.2%) fe-7
males and 149 (54.8%) males.
We genotyped four SNPs that had provided the most
significant results in the studies by Straub et al. (2002)
(P1635, P1325, P1320, and P1757) and Schwab et al.
(2003) (P1635, P1325, and P1320). One additional SNP,
P1578, was chosen on the basis of results from a recent
follow-up analysis of the Straub et al. (2002) data (van
den Oord et al. 2003), in which this SNP was identified
as a tag SNP for a high-risk haplotype for schizophrenia.
Because no odds ratio/relative risk information was
given by Straub et al. (2002), we could not calculate the
power of our sample to replicate their findings. However,
Schwab et al. (2003) reported effect sizes for their as-
sociated SNPs (P1635, P1325, and P1320) and, on the
basis of their figures, we calculated, using the Genetic
Power Calculator (Purcell et al. 2003), that the German
sample had a power of 0.93 to replicate their finding
for P1325, 0.84 for P1320, and 0.76 for P1635 at a
nominal significance level of .05, under the assumption
that there is no influence of family history of disease.
Under the same assumptions, the Polish sample had a
power of 0.78, and the Swedish sample a power of 0.54
to replicate the finding for P1325.
SNPs were genotyped using the Pyrosequencing tech-
nique (Pyrosequencing), which employs a primer exten-
sion method and an indirect bioluminiscent assay of py-
rophosphate (PPi) that is naturally released during DNA
synthesis. Released PPi is detected by a cascade of en-
zymatically induced reactions, generating a light pulse
that is recorded and displayed as a peak in a pyrogram.
Detailed information on PCR primer and extension
primer sequences as well as PCR/primer extension
conditions can be obtained on request. Marker-trait as-
sociation analysis was performed with the program
COCAPHASE 2.35 (Dudbridge 2002). Using a standard
unconditional logistic regression, this software package
performs likelihood ratio tests under a log-linear model
of the probability that an allele or a haplotype belongs
to the case rather than the control group; the expectation
maximization (EM) algorithm is used to resolve uncer-
tain haplotypes and provides maximum-likelihood es-
timates of frequencies. Results for the single-marker
analyses were confirmed with the Cochrane-Armitage
trend test (Armitage 1955). For the haplotype analysis,
we analyzed two-, three-, and four-marker haplotypes
from adjacent SNPs in a sliding-window fashion, as well
1440 Am. J. Hum. Genet. 73:1438–1443, 2003
Table 1
















n p 272 Pe
P1635 rs3213207 A/G .109 .137 .130 .111 .110 1.000 .115 .113 .915
P1325 rs1011313 C/T .105 .086 .271 .120 .106 .624 .110 .068 .032f
P1757 rs2005976 G/A .202 .240 .122 .177 .137 .261 .208 .169 .178
P1320 rs760761 C/T .214 .249 .141 .190 .152 .235 .220 .199 .512
P1578 rs1018381 C/T .072 .078 .678 .053 .027 .124 .085 .061 .213
a Described by Straub et al. (2002).
b National Center for Biotechnology Information, Single Nucleotide Polymorphism Database.
c Second allele is the less frequent allele.
d Frequency of the less frequent allele.
e Calculated by COCAPHASE.
f Underlining indicates difference between cases and controls reached statistical significance. P p .124 after adjustment for multiple testing
through permutation.
Table 2
Global P Values for Haplotype Analysis of Dysbindin SNPs in the Total Sample and Subgroup
















1_2 .198 .408 .761 .512 .068 .780
2_3 .149 .870 .526 .897 .014 (.038)c .012
3_4 .197 .798 .608 .523 .427 .020
4_5 .202 .584 .276 .305 .154 .003 (.009)c
1_2_3 .225 .421 .295 .385 .021 (.033)c .009
2_3_4 .096 .887 .845 .928 .064 .023
3_4_5 .248 .398 .368 .432 .092 .0004 (.001)c
1_2_3_4 .168 .448 .683 .948 .083 .006
2_3_4_5 .113 .506 .656 .933 .033 (.045)c .0009 (.0016)c
1_2_3_4_5 .178 .543 .342 .833 .0098 .0009
NOTE.—Significance was calculated by COCAPHASE.
a 1p P1635; 2p P1325; 3p P1757; 4p P1320; and 5p P1578.
b FH indicates individuals with family history of schizophrenia.
c Underlining indicates difference reached statistical significance. Significance of the best result in
the respective sliding-window analysis, corrected for multiple testing by permutation.
as the complete five-marker haplotype of all analyzed
SNPs. Since the EM algorithm does not accurately es-
timate haplotype frequencies !1% (Fallin and Schork
2000), such haplotypes were excluded. Individuals with
missing genotype information at any of the five loci were
excluded from the haplotype analysis. For the single-
marker analyses, a permutation procedure was used to
estimate the significance of the best results, correcting
for the five loci tested. For the haplotype analyses, the
global null hypotheses that all odds ratios are equal were
also tested by permutation, owing to the fact that esti-
mated haplotype frequencies cannot be treated as ob-
served data. Furthermore, the permutation procedure
was used to estimate the significance of the best result
from the 2-, 3-, and 4-marker sliding window analyses,
correcting for the number of windows tested. The per-
mutation method implemented in COCAPHASE ran-
domly reassigns the “case” and “control” labels in the
actual data. Ten thousand permutations were performed
in each permutation analysis.
Each of the three samples was analyzed separately,
because a comparison of SNP allele frequencies in the
controls revealed significant differences for some of the
SNPs (German vs. Swedish controls: P1757 [ ];Pp .025
German vs. Polish controls: P1757 [ ], P1320Pp .002
[ ], P1578 [ ]; Polish vs. Swedish con-Pp .003 Pp .009
trols: P1578 [ ]). All SNPs were in Hardy-Wein-Pp .046
berg equilibrium in both the case and control samples.
None of the five investigated SNPs showed association
with schizophrenia in the German and Polish samples
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Table 3
Allele Frequencies of Five SNPs in the Dysbindin Gene in Case-Control Samples from Germany, Sweden, and Poland with a Family
History of Schizophrenia













n p 272 Pd
P1635 rs3213207 A/G .181 .137 .242 .105 .110 .915 .125 .113 .771
P1325 rs1011313 C/T .090 .086 .853 .158 .106 .243 .065 .064 .987
P1757 rs2005976 G/A .259 .240 .677 .197 .137 .226 .297 .169 .018e
P1320 rs760761 C/T .255 .249 .904 .208 .152 .271 .293 .199 .110
P1578 rs1018381 C/T .054 .078 .343 .079 .027 .063 .156 .061 .013f
a Described by Straub et al. (2002).
b Second allele is the less frequent allele.
c Frequency of the less frequent allele.
d Calculated by COCAPHASE.
e Underlining indicates difference reached statistical significance.
f Underlining indicates difference reached statistical significance. P p .068 after adjustment for multiple testing through permutation.
Table 4
Dysbindin Haplotype Frequencies in the Swedish






( )np 272 Pb
1_2_3_4_5
A_C_G_C_C .643 .753 .09
A_C_A_T_C .018 .024 .84
A_C_A_T_T .178 .031 .00009c
A_T_G_C_C .051 .060 .85
G_C_A_T_C .107 .094 .09
a 1 p P1635; 2 p P1325; 3 p P1757; 4 p
P1320; 5 p P1578.
b Calculated by COCAPHASE.
c Underlining indicates difference reached statis-
tical significance.
in single-marker (table 1) and haplotype analyses (table
2). In the Swedish sample, P1325 reached significance
( ; table 1). However, the permutation analysisPp .032
adjusting for the five loci tested revealed a nonsignificant
P value of .124. On the other hand, haplotype analyses
clearly showed evidence of an association, the most sig-
nificant haplotype combination being the five-marker
haplotype ( ; table 2).Pp .0098
In accordance with the hypothesis that a stratification
of the samples with regard to a family history of schizo-
phrenia might have a higher chance of replicating the
association finding, we performed a separate analysis with
the family history–positive subgroups. “Positive fam-
ily history” was defined as having at least one first- or
second-degree relative with schizophrenia. There were 56
(13.4% of the total sample) family history–positive in-
dividuals in the German, 38 (12.9%) in the Polish, and
32 (22.5%) in the Swedish sample. No association was
found in the German and Polish subsamples. In the Swed-
ish sample, however, frequencies of the rare alleles were
significantly higher for P1757 ( ) and P1578 inPp .018
the patients with schizophrenia ( ) (table 3). AfterPp .013
adjusting for multiple testing by permutation across the
five analyzed markers, the marker with the best result
(P1578) did not reach significance ( ). ConclusivePp .068
results were obtained from the haplotype analyses. Several
haplotypes showed significant global P values, the five-
marker haplotype P1635-P1325-P1757-P1320-P1578
showing (table 2). This P value remains sig-Pp .0009
nificant, even after applying a Bonferroni correction for
the number of samples (three) and haplotype combina-
tions (four) tested ( ). Given this result, we werePp .0108
interested in the contribution of individual haplotypes to
the global result. Thus, individual haplotypes were tested
for association by grouping all others together and ap-
plying the x2 test with 1 df. Results of this analysis are
given in table 4. The most significant haplotype was A-
C-A-T-T, which occurs at a frequency of 3.1% in the
controls, and 17.8% in the cases ( ;Pp .00009 Pp
after Bonferroni correction). The possibility has.00153
been discussed that, given a population with significant
association, an improvement in P value may exist in ran-
dom subsets of the population (Johnson et al. 2002). To
test whether the improvement observed in familial cases
could have arisen by chance alone, we randomly chose
32 individuals from the Swedish sample (10,000 repli-
cates). Only 68 replicates showed a P value equal to or
smaller than that of the observed subgroup with a family
history of schizophrenia, suggesting that our observation
is unlikely to be a chance finding ( ).Pp .0068
Although the associated haplotype in the Swedish
sample is not exactly the same as the ones reported in
the Irish (G-C-A-T-C) (van den Oord et al. 2003) and
German populations (A-C-X-C-C [“X” is marker P1757,
which was not genotyped in that study]) (Schwab et al.
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2003), phylogenetic tree analysis shows a close rela-
tionship between the risk haplotype in the Swedish pop-
ulation and the Irish population (data not shown). The
risk haplotype A-C-A-T-T has an odds ratio of 6.75 in
the Swedish population.
In light of the findings described elsewhere (Straub et
al. 2002; Morris et al. 2003; Schwab et al. 2003), our
data suggest that genetic variation in the dysbindin gene
is particularly involved in the development of schizo-
phrenia in cases with a familial loading of the disease.
This would also explain the difficulty of replicating the
association in consecutively ascertained case-control
samples, which usually comprise only a relatively small
proportion of cases with a positive family history of
schizophrenia. Morris et al. (2003), for example, strat-
ified their sample with regard to family history of schizo-
phrenia but found no evidence of association. However,
owing to the small sample size (65 of 219 cases [29.7%
of the original sample size]), they could not make any
firm conclusions. If medium-sized case-control samples
are subdivided according to family history, the inevitable
result is an enormous loss of statistical power. In our
study, the German familial subsample ( ) had anp 56
power of only 35% to replicate the effect for marker
P1325 reported by Schwab et al. (2003). The Polish
subsample ( ) had a power of 29%, and the Swed-np 38
ish subsample ( ) had a power of 19%. Given thenp 32
small power of the subsamples, it is not surprising that
we find association in only one of three samples; on the
contrary, it meets the expectation.
Interestingly, an effect of family history has also been
suggested for the involvement of the neuregulin 1 gene
in schizophrenia by Williams et al. (2003), who were
able to replicate an association that was originally re-
ported by Stefansson et al. (2002). Williams et al. (2003)
found a borderline significant association of a particular
haplotype in a large collection of 573 schizophrenia cases
and 618 controls ( ), which became stronger whenPp .04
the subset of 141 cases with a family history of schizo-
phrenia was analyzed ( ).Pp .019
Recently, numerous gene identification studies have
been following the positional-candidate paradigm, in
which initial evidence of a gene locus is obtained from
linkage analyses in families loaded with the disease under
study. In the subsequent step, association analyses are
performed, to eventually identify genetic variants that
confer risk of disease. Our results show that it could be
crucial for the success of these studies to use association
samples enriched for familial cases instead of consecu-
tively ascertained cases, which normally include only a
small proportion of individuals with a family history of
disease.
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